US5206344A
(en)
*
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
CA1283046C
(en)
*
|
1986-05-29 |
1991-04-16 |
Nandini Katre |
Tumor necrosis factor formulation
|
US4745180A
(en)
*
|
1986-06-27 |
1988-05-17 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using heparin fragments
|
US5004605A
(en)
*
|
1987-12-10 |
1991-04-02 |
Cetus Corporation |
Low pH pharmaceutical compositions of recombinant β-interferon
|
US4847325A
(en)
*
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
IE62463B1
(en)
*
|
1988-07-07 |
1995-02-08 |
Res Dev Foundation |
Immunoconjugates for cancer diagnosis and therapy
|
US5091176A
(en)
*
|
1988-11-02 |
1992-02-25 |
W. R. Grace & Co.-Conn. |
Polymer-modified peptide drugs having enhanced biological and pharmacological activities
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
ATE135370T1
(de)
*
|
1988-12-22 |
1996-03-15 |
Kirin Amgen Inc |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
US4902502A
(en)
*
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
WO1990015628A1
(en)
*
|
1989-06-14 |
1990-12-27 |
Cetus Corporation |
Polymer/antibiotic conjugate
|
JPH04506662A
(ja)
*
|
1989-07-14 |
1992-11-19 |
アメリカン・サイアナミド・カンパニー |
接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
ES2069082T3
(es)
*
|
1989-08-07 |
1995-05-01 |
Debio Rech Pharma Sa |
Derivados polimericos de farmacos biologicamente activos.
|
US5393735A
(en)
*
|
1990-08-09 |
1995-02-28 |
Rohm And Haas Company |
Herbicidal glutarimides
|
US5552391A
(en)
*
|
1990-01-16 |
1996-09-03 |
La Jolla Pharmaceutical Company |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
FR2658519B1
(fr)
*
|
1990-02-19 |
1995-07-07 |
Serbio |
Substrats peptidiques pour identification du facteur xa.
|
FR2658521B1
(fr)
*
|
1990-02-19 |
1994-01-21 |
Serbioo |
Bipeptides symetriques comportant un reste polyalkyleneglycol, procede de preparation et utilisation dans le dosage des proteases.
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5312903A
(en)
*
|
1990-06-01 |
1994-05-17 |
E. I. Du Pont De Nemours And Company |
Lysine-glycosylated recombinant interleukin-2
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
US5229366A
(en)
*
|
1990-10-23 |
1993-07-20 |
Fuji Photo Film Co., Ltd. |
Peptide-containing polyethylene glycol derivatives and application thereof
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
EP0642798B1
(en)
*
|
1993-09-08 |
2007-04-18 |
La Jolla Pharmaceutical Company |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5446090A
(en)
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
US5629384A
(en)
*
|
1994-05-17 |
1997-05-13 |
Consiglio Nazionale Delle Ricerche |
Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
|
US20030053982A1
(en)
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US8071737B2
(en)
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
ES2336857T3
(es)
*
|
1995-05-04 |
2010-04-16 |
Gilead Sciences, Inc. |
Complejos de ligandos de acido nucleico.
|
US5874409A
(en)
|
1995-06-07 |
1999-02-23 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
US6004579A
(en)
*
|
1995-09-14 |
1999-12-21 |
Lxr Biotechnology, Inc. |
Compositions which inhibit apoptosis, methods of making the compositions and uses thereof
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
AU725133B2
(en)
*
|
1997-01-15 |
2000-10-05 |
Polaris Group |
Modified tumor necrosis factor
|
AU6326198A
(en)
|
1997-02-13 |
1998-09-08 |
Lxr Biotechnology Inc. |
Organ preservation solution
|
PT1421956E
(pt)
*
|
1998-04-28 |
2007-07-13 |
Serono Lab |
Processo para a ligação por passos de polietileno glicol ( peg ) a um polipéptido
|
US6858210B1
(en)
|
1998-06-09 |
2005-02-22 |
La Jolla Pharmaceutical Co. |
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
|
ATE298251T1
(de)
|
1998-08-06 |
2005-07-15 |
Mountain View Pharmaceuticals |
Peg-uricase konjugate und verwendung davon
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
TR200101086T2
(tr)
*
|
1998-10-16 |
2001-08-21 |
Biogen, Inc. |
Interferon beta-1A'nın polimer birleşikleri ve kullanımları.
|
SK287491B6
(sk)
|
1998-10-16 |
2010-11-08 |
Biogen Idec Ma Inc. |
Fúzne proteíny interferónu- beta-1a a ich použitie
|
US6458953B1
(en)
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
US6399578B1
(en)
|
1998-12-09 |
2002-06-04 |
La Jolla Pharmaceutical Company |
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
|
EP1328295A2
(en)
*
|
1999-08-27 |
2003-07-23 |
Maxygen Aps |
New interferon beta-like molecules
|
US7431921B2
(en)
|
2000-04-14 |
2008-10-07 |
Maxygen Aps |
Interferon beta-like molecules
|
US6531122B1
(en)
|
1999-08-27 |
2003-03-11 |
Maxygen Aps |
Interferon-β variants and conjugates
|
US7144574B2
(en)
|
1999-08-27 |
2006-12-05 |
Maxygen Aps |
Interferon β variants and conjugates
|
TR200101086A3
(US20100223739A1-20100909-C00025.png)
*
|
1999-10-15 |
2001-08-21 |
|
|
PL356007A1
(en)
|
1999-11-12 |
2004-05-31 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
YU32402A
(sh)
|
1999-11-12 |
2005-03-15 |
Maxygen Holdings Ltd. |
Konjugati gama interferona
|
KR100773323B1
(ko)
|
2000-01-10 |
2007-11-05 |
맥시겐 홀딩스 리미티드 |
지-씨에스에프 접합체
|
WO2001058935A2
(en)
|
2000-02-11 |
2001-08-16 |
Maxygen Aps |
FACTOR VII OR VIIa-LIKE MOLECULES
|
ZA200305980B
(en)
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
HUP0303251A2
(hu)
|
2001-02-27 |
2003-12-29 |
Maxygen Aps |
Béta-interferon-szerű molekulák
|
US7038015B2
(en)
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
JP4142569B2
(ja)
*
|
2001-06-22 |
2008-09-03 |
協和醗酵工業株式会社 |
軟膏剤
|
WO2003007889A2
(en)
|
2001-07-17 |
2003-01-30 |
Research Development Foundation |
Therapeutic agents comprising pro-apoptotic proteins
|
CA2456470A1
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
ES2411007T3
(es)
|
2001-10-10 |
2013-07-04 |
Novo Nordisk A/S |
Remodelación y glicoconjugación de péptidos
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
AU2004236174B2
(en)
|
2001-10-10 |
2011-06-02 |
Novo Nordisk A/S |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7399613B2
(en)
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
ZA200700168B
(en)
|
2001-10-10 |
2010-02-24 |
Novo Nordisk As |
Remodeling and glycoconjugation of peptides
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
ES2566797T3
(es)
|
2002-01-18 |
2016-04-15 |
Biogen Ma Inc. |
Compuestos de polímero de polialquileno y usos de éstos
|
UA86744C2
(en)
|
2002-06-21 |
2009-05-25 |
Ново Нордиск Хэлс Кеа Аг |
Pegylated factor vii glycoforms
|
AU2003239774A1
(en)
|
2002-07-03 |
2004-01-23 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
EA008866B1
(ru)
*
|
2002-12-26 |
2007-08-31 |
Маунтин Вью Фамэсьютикэлс, Инк. |
ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
|
BRPI0408358A
(pt)
|
2003-03-14 |
2006-03-21 |
Neose Technologies Inc |
polìmeros hidrossolúveis ramificados e seus conjugados
|
EP1613261A4
(en)
|
2003-04-09 |
2011-01-26 |
Novo Nordisk As |
INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
DE602004012424T2
(de)
*
|
2003-08-07 |
2009-04-30 |
Zymogenetics, Inc., Seattle |
Homogene herstellungen von il-29
|
AU2004266969B2
(en)
*
|
2003-08-25 |
2010-02-25 |
Taniguchi, Tadatsugu |
Interferon-beta composite
|
ATE481420T1
(de)
|
2003-10-10 |
2010-10-15 |
Novo Nordisk As |
Il-21-derivate
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
JP4719686B2
(ja)
|
2003-11-24 |
2011-07-06 |
バイオジェネリックス アーゲー |
GlycoPEG化エリスロポエチン
|
SG135176A1
(en)
|
2004-02-02 |
2007-09-28 |
Ambrx Inc |
Modified human four helical bundle polypeptides and their uses
|
RU2006138181A
(ru)
|
2004-05-04 |
2008-06-10 |
Ново Нордиск Хелс Кеа Аг (Ch) |
О-связанные гликоформы полипептидов и способ их изготовления
|
NZ551335A
(en)
|
2004-06-18 |
2010-03-26 |
Ambrx Inc |
Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
AU2009212311B8
(en)
|
2004-07-21 |
2013-05-30 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
ES2566670T3
(es)
|
2004-10-29 |
2016-04-14 |
Ratiopharm Gmbh |
Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
|
EP2284191A3
(en)
|
2004-12-22 |
2011-07-20 |
Ambrx, Inc. |
Process for the preparation of hGH
|
EP1858543B1
(en)
|
2005-01-10 |
2013-11-27 |
BioGeneriX AG |
Glycopegylated granulocyte colony stimulating factor
|
WO2006121569A2
(en)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
PL3321359T3
(pl)
|
2005-04-11 |
2021-06-28 |
Horizon Pharma Rheumatology Llc |
Wariantowe postacie oksydazy moczanowej i ich zastosowanie
|
US20080255026A1
(en)
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
EP2360170A3
(en)
|
2005-06-17 |
2012-03-28 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
EP2339014B1
(en)
|
2005-11-16 |
2015-05-27 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
RU2304586C1
(ru)
*
|
2006-03-27 |
2007-08-20 |
Михаил Николаевич Смирнов |
Препарат интерлейкина-2 и способ его получения
|
RU2322452C2
(ru)
*
|
2006-03-27 |
2008-04-20 |
Михаил Николаевич Смирнов |
Иммуномодулирующая композиция
|
US20090252720A1
(en)
|
2006-05-24 |
2009-10-08 |
Novo Nordisk Health Care Ag |
Prolonged FIX Analogues and Derivatives
|
US20080280818A1
(en)
|
2006-07-21 |
2008-11-13 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
|
AU2007296843C1
(en)
*
|
2006-09-15 |
2012-08-16 |
Creabilis Therapeutics S.P.A. |
Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
|
WO2008057683A2
(en)
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
EP2144923B1
(en)
|
2007-04-03 |
2013-02-13 |
BioGeneriX AG |
Methods of treatment using glycopegylated g-csf
|
ES2551123T3
(es)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Proceso mejorado para la producción de azúcares de nucleótido
|
NZ583276A
(en)
|
2007-08-27 |
2012-06-29 |
Biogenerix Ag |
Liquid formulations of granulocyte colony stimulating factor and polymer conjugates
|
MX338336B
(es)
|
2007-11-20 |
2016-04-07 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
CN101909601B
(zh)
*
|
2008-01-18 |
2013-06-26 |
陶氏环球技术公司 |
使用甲氧基聚乙二醇增强难溶性活性剂的水溶解度的方法
|
MX356129B
(es)
|
2008-01-22 |
2018-05-16 |
Araim Pharmaceuticals Inc |
Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
|
DK2257311T3
(da)
|
2008-02-27 |
2014-06-30 |
Novo Nordisk As |
Konjugerede Faktor VIII-Molekyler
|
EP2672260A1
(en)
|
2008-05-13 |
2013-12-11 |
Advanced Liquid Logic, Inc. |
Droplet actuator devices, systems and methods
|
PE20110426A1
(es)
|
2008-07-23 |
2011-07-01 |
Ambrx Inc |
Polipeptidos g-csf bovinos modificados
|
DK2342223T3
(en)
|
2008-09-26 |
2017-07-24 |
Ambrx Inc |
Modified animal erythropoietin polypeptides and their uses
|
BRPI0919031A2
(pt)
|
2008-09-26 |
2014-09-23 |
Ambrx Inc |
Micro-organismos e vacinas dependentes de replicação através do uso de aminoácidos não naturais
|
HUP1200205A3
(en)
|
2009-06-25 |
2012-09-28 |
Savient Pharmaceuticals |
Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
PE20121799A1
(es)
|
2009-12-21 |
2013-01-02 |
Ambrx Inc |
Polipeptidos de somatotropina porcina modificados y sus usos
|
WO2011107591A1
(en)
|
2010-03-05 |
2011-09-09 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
JP2013528374A
(ja)
|
2010-05-10 |
2013-07-11 |
パーシード セラピューティクス リミテッド ライアビリティ カンパニー |
Vla4のポリペプチド阻害剤
|
LT2605789T
(lt)
|
2010-08-17 |
2019-09-10 |
Ambrx, Inc. |
Modifikuoti relaksino polipeptidai ir jų panaudojimas
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
KR102591732B1
(ko)
|
2010-11-12 |
2023-10-19 |
넥타르 테라퓨틱스 |
Il-2 부분 및 중합체의 접합체
|
SG10201604160WA
(en)
|
2011-02-10 |
2016-07-28 |
Roche Glycart Ag |
Mutant Interleukin-2 Polypeptides
|
EP2726502A1
(en)
|
2011-07-01 |
2014-05-07 |
Bayer Intellectual Property GmbH |
Relaxin fusion polypeptides and uses thereof
|
MX2014010209A
(es)
|
2012-02-29 |
2014-11-21 |
Toray Industries |
Agente inhibidor para acumulacion de fluido de la cavidad corporal.
|
KR102137290B1
(ko)
|
2012-04-16 |
2020-07-23 |
캔탭 바이오팔마수티칼 패턴트 리미티드 |
최적화된 피하 치료약
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
SG11201408161RA
(en)
|
2012-06-08 |
2015-01-29 |
Sutro Biopharma Inc |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
CN104981254B
(zh)
|
2012-08-31 |
2018-05-22 |
苏特罗生物制药公司 |
含有叠氮基的经修饰的氨基酸
|
WO2014201378A1
(en)
*
|
2013-06-13 |
2014-12-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
SI3412302T1
(sl)
|
2014-10-24 |
2021-09-30 |
Bristol-Myers Squibb Company |
Modificirani FGF-21 polipeptidi in njihova uporaba
|
EP3448415A4
(en)
|
2016-04-29 |
2019-11-06 |
Araim Pharmaceuticals, Inc. |
TISSUE PROTECTIVE PEPTIDES FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE INJURY
|
BR112019016139A2
(pt)
|
2017-02-08 |
2020-04-07 |
Bristol-Myers Squibb Company |
polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
PE20191494A1
(es)
|
2017-04-03 |
2019-10-21 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
|
TW201930345A
(zh)
*
|
2017-12-27 |
2019-08-01 |
日商協和醱酵麒麟有限公司 |
Il-2改型體
|
SI3849614T1
(sl)
|
2018-09-11 |
2024-04-30 |
Ambrx, Inc. |
Polipeptidni konjugati interlevkina-2 in njihove uporabe
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
BR112021012472A2
(pt)
|
2019-01-28 |
2021-11-30 |
Toray Industries |
Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
|
WO2020158690A1
(ja)
|
2019-01-28 |
2020-08-06 |
東レ株式会社 |
肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
|
AU2020223031A1
(en)
|
2019-02-12 |
2021-08-19 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-TLR agonist conjugates
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体
|
MX2022011163A
(es)
|
2020-03-11 |
2022-10-18 |
Ambrx Inc |
Conjugados de polipeptidos de interleucina-2 y sus usos.
|
US20230192795A1
(en)
|
2020-04-15 |
2023-06-22 |
Hoffmann-La Roche Inc. |
Immunoconjugates
|
US20230181712A1
(en)
|
2020-05-11 |
2023-06-15 |
Hoffmann-La Roche Inc. |
Combination therapy with modified pbmcs and an immunoconjugate
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
CA3197740A1
(en)
|
2020-12-04 |
2022-06-09 |
F. Hoffman-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
IL312005A
(en)
|
2021-10-14 |
2024-06-01 |
Hoffmann La Roche |
NEW INTERLEUKIN-7 IMMUNOCONJUGATES
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|